BioTalk is a news hub brought to you by Bird & Bird's International Life Sciences & Healthcare Group. Read more about us >

Transfer of value: amendments to the French “anti-gift” provisions by the draft Health Act

Healthcare 2 min
July 2, 2019

The French so-called “anti-gift” provisions strictly frame the conditions under which companies in the health sector are allowed to provide advantages, in cash or in kind, to healthcare professionals (“HCPs”), as well as to students, associations, public servants, etc.

The “anti-gift” provisions were amended by an order of 19 January 2017 that officially entered into force on 1 July 2018.

In practice, the actual application of these provisions is subject to the publication of the corresponding implementing texts, which still remain awaited. This transitional situation gives rise to many uncertainties for companies active in the health sector.

The “anti-gift” provisions are about to be amended again in the framework of the upcoming Act relating to the organization and transformation of the health system (the “Health Act”), which is currently under discussion in Parliament.

The main changes to the “anti-gift” provisions arising from the draft Health Act are:

1. The inclusion of the following persons within the scope of the “anti-gift” rules:

  • any person manufacturing or marketing health products in the field of competence of the French Medicines Agency (“ANSM“), regardless of whether they are funded under the social security scheme (this is already the case under the 2017 order);

and

  • any person manufacturing or marketing health products funded under the social security scheme, regardless of whether they fall in the ANSM’s field of competence.

The aim of this amendment is to include companies manufacturing or marketing certain products, such as nutrition products, which are reimbursed through social security but that are not in the field of competence of the ANSM, within the scope of the “anti-gift” provisions.

2. A complete prohibition on providing hospitality, such as in the framework of professional, scientific and promotional events, to students training to become HCPs and student associations.

3. Specification that the amount under which a transfer of value will be considered “negligible”, and therefore not considered an advantage under the “anti-gift” provisions, will be set for a given period of time (i.e. a sum not to be exceeded over said time period).

The next public discussion of the text will take place on 10 July 2019.

Written by
Dora Talvard
Dora Talvard
My work is focused on the life sciences and healthcare sectors. I advise clients on a broad range of regulatory aspects. I work hand in hand with the intellectual property, data protection, commercial and corporate lawyers of the firm to provide clients with tailor made advice and solutions.

Related articles

“Effective enforcement of EU competition rules in the pharmaceutical law remains a matter of high priority…”
So notes the Commission's report on competition enforcement in the pharmaceutical sector (2009-2017)...
Hungary: New Legal Provisions set out Mandatory Infrastructure for Telemedicine
Until recently the Hungarian legal background of telemedicine was not particularly detailed. For obvious...
Manufacturing and stockpiling waiver set to limit rights of holders of SPCs for medicines
On 17 April 2019, the European Parliament approved, by a large majority, an amendment of the Regulation...